Adolfo D. L. F.
- Country
- Spain
- Department
- Hematology
Research Overview
- Dose-Escalation and Expansion Study of BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein Degrader, in Patients with B-Cell Malignancies
- Phase 2/3 Randomized Study of Pivekimab Sunirine Plus Venetoclax and Azacitidine in Adults with Newly Diagnosed AML Ineligible for Intensive Chemotherapy
- Evaluation of RVU120 and Venetoclax Combination Therapy in Acute Myeloid Leukemia Patients Refractory to Prior Venetoclax and Hypomethylating Agent Treatment
Data & Insights
Has run more than one trial at 175 of 436 partner sites.
Specializations
Acute Myeloid Leukemia
The investigator specializes in treating acute myeloid leukemia (AML), with particular focus on novel therapeutic approaches for both newly diagnosed and relapsed/refractory cases. Their research encompasses targeted therapies including Menin-MLL inhibitors and combination treatments with established agents.
- Relapsed/Refractory AML
- NPM1-mutated AML
- CD123-positive AML
Lymphoid Malignancies
The investigator has extensive experience in treating various B-cell malignancies, including innovative approaches for aggressive and indolent lymphomas. Their work includes studies of novel antibody therapies and targeted agents for multiple lymphoma subtypes.
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Chronic Lymphocytic Leukemia
Myelodysplastic Syndrome
The investigator conducts research in myelodysplastic syndrome (MDS), particularly focusing on higher-risk disease. Their work includes studies of novel therapeutic combinations and targeted approaches for specific molecular subtypes.
- Higher-risk MDS
- RARA-positive MDS
- Refractory MDS
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.